1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,520 | 2,760 | 09:32 | |
| 2,540 | 2,740 | 09:08 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.10. | Addex-Spin-out Neurosterix schliesst Phase-1-Studie ab | 7 | cash | ||
| ADDEX THERAPEUTICS SA ADR Aktie jetzt für 0€ handeln | |||||
| 08.10. | Addex Therapeutics: Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia | 487 | GlobeNewswire (Europe) | Ad Hoc Announcement Pursuant to Art.?53 LR
Geneva, Switzerland, October 8, 2026
-
Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on... ► Artikel lesen | |
| 02.10. | Addex Therapeutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 02.10. | Addex Therapeutics Announces Executive Management Changes | 418 | GlobeNewswire (Europe) | Jean-Philippe Rocher Appointed Head of Pharmaceutical DevelopmentMikhail Kalinichev, Head of Translational Science, Steps Down
Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland... ► Artikel lesen | |
| 30.09. | Addex Therapeutics Raises $2.8 Million As GABAB Programs Advance | 4 | pulse2.com | ||
| 28.09. | Addex Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript | 2 | Benzinga.com | ||
| 28.09. | Addex Therapeutics H1 Net Loss Widens, Operating Loss Narrows; Advances GABAB PAM Cough Program | 2 | RTTNews | ||
| 28.09. | Addex Therapeutics reports 1H results | 6 | Seeking Alpha | ||
| 28.09. | Addex bringt Programme im zweiten Quartal weiter voran | 418 | Moneycab | Genf - Das Biotechunternehmen Addex ist im zweiten Quartal erwartungsgemäss in den roten Zahlen geblieben. Die liquiden Mittel beliefen sich per Ende Juni 2026 auf 0,8 Millionen Franken. Einnahmen verbuchte... ► Artikel lesen | |
| 28.09. | Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update | 420 | GlobeNewswire (Europe) | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, September 28, 2026
-
Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| 25.09. | Indivior ends PAM drug collab with Addex ahead of Supernus merger | 1 | FierceBiotech | ||
| 25.09. | Addex Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 25.09. | Addex-Chef sieht Rückgabe von GABAB-Programm positiv | 3 | cash | ||
| 25.09. | Addex Therapeutics: Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior | 498 | GlobeNewswire (Europe) | Ad Hoc Announcement Pursuant to Art.?53 LR
Geneva, Switzerland, September 25, 2026
-
Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company developing... ► Artikel lesen | |
| 24.09. | Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026 | 485 | GlobeNewswire (Europe) | Geneva, Switzerland, September 24, 2026
-
Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric... ► Artikel lesen | |
| 28.08. | Addex beschafft sich im Rahmen seines ATM-Vertrags 2,8 Millionen US-Dollar | 612 | Moneycab | Genf - Addex Therapeutics (SIX und Nasdaq: ADXN), ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich auf die Entwicklung eines Portfolios neuartiger kleinmolekularer allosterischer... ► Artikel lesen | |
| 26.08. | Addex Therapeutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 26.08. | Addex Therapeutics raises $2.8M via ATM offering, extending runway to Q4 2027 | 1 | Seeking Alpha | ||
| 26.08. | Addex Therapeutics: ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027 | 572 | GlobeNewswire (Europe) | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, August 26, 2026
-
Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| 08.07. | Addex Therapeutics Ltd. - 6-K, Report of foreign issuer | 6 | SEC Filings |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QUANTUM BIOPHARMA | 1,983 | -3,46 % | Quantum BioPharma Signs Contract with Thermo Fisher Scientific's Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis | TORONTO, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) ("Quantum BioPharma"), a biopharmaceutical company focused on developing innovative therapies and technologies... ► Artikel lesen | |
| JAGUAR HEALTH | 2,280 | 0,00 % | Jaguar Health, Inc.: Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure in Third Rare Congenital Enteropathy Disorder | Mutation of the GUCY2C gene is the third IF-related congenital enteropathy, in addition to microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF), for which crofelemer has demonstrated... ► Artikel lesen | |
| LIPOCINE | 1,600 | 0,00 % | Lipocine Inc. - 8-K, Current Report | ||
| THERAPEUTICSMD | 1,620 | +1,25 % | TherapeuticsMD, Inc. - 10-Q, Quarterly Report | ||
| ALLARITY THERAPEUTICS | 0,880 | +1,07 % | Allarity Therapeutics, Inc.: Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research | - Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib - New proteomics and cell line capabilities will broaden Allarity's research capabilities to enable... ► Artikel lesen | |
| EXICURE | 0,905 | -2,16 % | Exicure, Inc.: Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance | WILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) ("Exicure" or the "Company") today announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics... ► Artikel lesen | |
| COSMOS HEALTH | 0,257 | +2,31 % | Cosmos Health Inc.: Cosmos Health CEO Greg Siokas Issues Letter to Shareholders Highlighting Record 2026 Revenue, U.S. Subscription Growth and Global Expansion | Key HighlightsRecord revenue: preliminary nine-month 2026 revenue of approximately $54.3 million, up 19%, with every quarter of 2026 setting a record2026 outlook reaffirmed: full-year revenue expected... ► Artikel lesen | |
| 60 DEGREES PHARMACEUTICALS | 0,890 | -2,72 % | 60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA | After a scheduled interim analysis of the severe babesiosis study on October 1, 2026, the DSMB recommended completing the study with the originally planned number of patients (N=33); the study remains... ► Artikel lesen | |
| SUNSHINE BIOPHARMA | 0,215 | 0,00 % | Sunshine Biopharma Inc.: Sunshine Biopharma Announces Closing of up to $20.4 Million Public Offering | $6.0 million upfront with an additional $14.4 million of potential aggregate gross proceeds upon the exercise of warrants FORT LAUDERDALE, FL / ACCESS Newswire / October 9, 2026 / Sunshine Biopharma... ► Artikel lesen | |
| CELLYAN BIOTECHNOLOGY | 0,105 | +3,14 % | Cellyan Biotechnology announces 1-for-20 reverse stock split | ||
| SHUTTLE PHARMACEUTICALS | 4,880 | +1,24 % | Shuttle Pharmaceuticals Holdings Inc.: United Dogecoin Purchases Dogecoin Miners and Secures Renewable Energy Data Centre Site | Gaithersburg, Maryland--(Newsfile Corp. - June 26, 2026) - United Dogecoin Inc. ("United Dogecoin" or the "Company"), a Dogecoin mining company driven by industry experts recently acquired by Shuttle... ► Artikel lesen | |
| TEVA PHARMACEUTICAL INDUSTRIES | 40,590 | -0,06 % | Teva/Sanofi: Duvakitug Maintains Meaningful Efficacy Improvements In Long-term Extension Study | PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), and Sanofi announced new positive data from the RELIEVE UCCD phase 2b long-term extension... ► Artikel lesen | |
| OMNIAB | 4,910 | -0,10 % | OmniAb auf der LD Micro Konferenz: Lizenzgebühren, Skalierung und Geduld im Fokus | ||
| AQUESTIVE THERAPEUTICS | 4,080 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung für Aquestive nach FDA-Fortschritten | ||
| BAYER | 44,150 | -1,08 % | Bayer nach 15 % Kursverlust Stabilisierung an der 200-Tage-Linie | Nach dem Rückgang von mehr als 15 % hat sich die Bayer-Aktie im Bereich der 200-Tage-Linie stabilisiert. Gleichzeitig bleibt der Bruch der früheren Unterstützung und die weiterhin neutrale Korrekturphase... ► Artikel lesen |
Das Unternehmen ADDEX THERAPEUTICS SA ADR kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 2,620 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADDEX THERAPEUTICS SA ADR finden Sie auf Wallstreet Online.